With his new album, “After the Fire,” associate professor of hip hop A.D. Carson explores what it means to be a human performer at a time when AI and other technological tools can rival the creations of live artists.
After 16 years of research and clinical testing, a School of Medicine diabetes expert has authored a book detailing how people with pre-diabetes or type 2 diabetes can manage their condition without the need for weight loss, insulin, medication or supplements.
A new UVA Health study reveals that calls to poison centers involving liver injuries from medications, supplements, alcohol, and other substances surged nearly 400% between 2000 and 2024. Acetaminophen was the leading cause, with suspected suicide the most common reason for exposure. Alcohol ranked second, with cases rising during the COVID-19 pandemic. Over 80% of cases required inpatient care.
UVA Health researchers have discovered how postoperative delirium may trigger dementia in older patients and identified a potential drug to reverse the underlying brain changes. The study found that anesthesia, surgery, and intensive care stress alter gene activity in aged brains, disrupting memory and sleep regulation. Vorinostat, an FDA-approved cancer drug, reversed many of these harmful changes in mice.
Qnovia, Inc., a clinical-stage pharmaceutical company, today announced it has secured a worldwide exclusive license to an innovative antimicrobial peptide from the University of Virginia Licensing & Ventures Group. The license marks Qnovia’s expansion into a second major therapeutic area, complementing its lead smoking cessation program as the company pursues breakthrough solutions to population-scale health challenges.
UVA Health researchers have found that gliomas, the most common primary brain tumors in adults, may be more receptive to focused ultrasound drug delivery than normal brain tissue.
GET THE STORIES BEHIND THE RESEARCH
Receive updates about the discoveries, researchers, and ideas shaping our world — straight from UVA.
A University of Virginia School of Medicine scientist has received a $6.5 million grant to develop the “lymphatic medicine exam of the future” to improve care for chronic swelling, known as lymphedema, and other lymphatic diseases.
UVA scientists have developed a promising new approach to targeting glioblastoma, the most common and deadliest brain cancer, that could overcome limitations of existing drugs.
With artificial intelligence being adopted rapidly by healthcare organizations around the country, a UVA Health doctor and colleague at Clemson University have developed a framework to ensure that the technology is implemented in a way that ensures patient care remains the top priority.
New research from UVA’s Melanie Rutkowski, PhD, and colleagues helps explain how the gut microbiome – the collection of microorganisms that live in and on our intestines – plays a role in the spread of hormone receptor-positive (HR+) breast cancer.
Unusual gene changes may help explain stroke-causing cervical artery dissections and could lead to new ways to prevent debilitating strokes among the young.
When University of Virginia graduate student Caeley Reever came across the word “stellular” – “little star” in Latin – she and UVA anesthesiology professor Manoj Patel knew they had the perfect name for their startup company.
Stellula Therapeutics is centered around developing a gene therapy for a rare pediatric genetic epilepsy disorder, SCN8A developmental and epileptic encephalopathy.